| Literature DB >> 35585949 |
Takuma Tsuzuki Wada1, Kazuhiro Yokota1, Shinichiro Iida2, Yuki Kanno3, Nozomi Shinozuka3, Kojiro Sato1,4, Yu Funakubo Asanuma1, Keiji Yamamoto2, Toshihide Mimura1.
Abstract
Introduction: Most pulmonary vasodilators are administered orally; however, in patients with pulmonary hypertension undergoing gastrointestinal surgery, a switch to parenteral drugs is needed. Parenteral pulmonary vasodilators carry a risk of infection and reduced quality of life owing to long-term central venous catheterization; therefore, it is preferable to switch them to oral vasodilators after surgery. Here, we present the case of a patient with systemic sclerosis complicated by pulmonary hypertension and colon cancer, for which treatment was successfully switched from epoprostenol to selexipag postoperatively. Case Description: A 59-year-old woman, who was diagnosed with mixed group I and III pulmonary hypertension and systemic sclerosis, was on oral triple pulmonary vasodilators for pulmonary hypertension and Raynaud's phenomenon. She was diagnosed as having colon cancer 3 months before admission. Despite the severe pulmonary condition and treatment with oral triple pulmonary vasodilators, colon cancer resection surgery was performed with the management for pulmonary hypertension through multidisciplinary treatments in collaboration with cardiology specialists. Medications for patients with pulmonary hypertension undergoing gastrointestinal surgery need to be switched from oral vasodilators to epoprostenol perioperatively. On postoperative day 19, 0.4 mg/day of selexipag was administered with epoprostenol. Subsequently, the epoprostenol dosage was gradually decreased, and selexipag was increased. On postoperative day 30, the dose of selexipag was increased to 1.2 mg/day and epoprostenol was discontinued. The patient was discharged on postoperative day 40.Entities:
Keywords: Pulmonary hypertension; epoprostenol; perioperative management; selexipag; systemic sclerosis
Year: 2021 PMID: 35585949 PMCID: PMC9109508 DOI: 10.1177/23971983211063711
Source DB: PubMed Journal: J Scleroderma Relat Disord ISSN: 2397-1983